# Eloxx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eloxx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Watertown, US
- Website: www.eloxxpharma.com
- Total disclosed funding: $14M
- Latest round: Series C (Aug 2, 2017)
- Investors on record: 8

## About

Eloxx Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing innovative ribosome-targeted genetic therapies to address genetic defects associated with rare diseases and cancers.Founded in 2013 in Watertown, US, Eloxx Pharmaceuticals focuses on developing therapies targeting nonsense mutations and ribosomal mutations related to various genetic disorders and cancers. The company has undergone significant funding rounds, with its latest notable fundraising of USD 15.90 mn in a GRANT led by the Cystic Fibrosis Foundation. Eloxx has raised a total of USD 30.00 mn to date.Eloxx Pharmaceuticals specializes in developing ribosome-targeted genetic therapies aimed at correcting genetic defects associated with rare diseases and cancer. Their lead product, TURBO-ZM™, enhances mRNA translation to restore proper protein synthesis and function. These therapies target patients suffering from genetic diseases and malignancies, and Eloxx's products are marketed in North America and Europe to healthcare providers, specialty pharmacies, and research institutions.In the most recent financial year of 2016, Eloxx Pharmaceuticals reported a revenue of USD 75,000, while the EBITDA for the same year was reported at USD -33,183,000.Eloxx Pharmaceuticals plans to utilize its most recent funding of USD 15.90 mn to further develop its platform technology and upcoming product launches. The company aims to expand its market presence, particularly targeting additional regions in North America and Europe by the end of 2023. Recent funding will support these initiatives, following the completion of an IPO in April 2018 that raised USD 50.02 mn, highlighting the company's ongoing commitment to advancing its innovative therapies.

## Funding rounds

- Series C, Aug 2, 2017, $8M — EQT Life Sciences, Pontifax Venture Capital, Korea Investment Partners, Opko Health, Inc., DSC Investment, Catalyst, Quark Venture
- Series C, Jun 26, 2017, $6M — Pontifax Venture Capital, Korea Investment Partners, DSC Investment
- Series A, Nov 21, 2013 — Pontifax Venture Capital, Roche Holding Ltd

## Investors

- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series C
- Roche Holding Ltd — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series C
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series C
- Opko Health, Inc. — Series C
- Catalyst (https://capitalatlas.ai/funds/catalyst) — Series C
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series C